Opinion

Results from the IMpassion132 trial presented at ESMO Breast 24

Photo taken from ESMO/LinkedIn

May 18, 2024, 01:12

Results from the IMpassion132 trial presented at ESMO Breast 24

The European Society for Medical Oncology (ESMO) shared on LinkedIn:

“Results from the IMpassion132 trial presented at ESMO Breast 24 reveal that adding atezolizumab to chemotherapy does not improve overall survival in patients with advanced triple-negative breast cancer (TNBC) relapsing within 12 months after initial treatment.
However, according to Carmen Criscitiello, the higher objective response rate achieved with atezolizumab suggests that at least some patients could benefit from it, and this highlights the importance of individualised treatment approaches.

Read more in the ESMO Daily Reporter article.”

Source: ESMO/LinkedIn
OncoDaily

Advanced triple-negative breast cancer (TNBC) atezolizumab cancer carmen criscitiello chemotherapy ESMO Breast 24 ESMO Daily Reporter European Society for Medical Oncology (ESMO) IMpassion132 trial Individualized treatment approaches objective response rate OncoDaily Oncology overall survival Relapse

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage